Advertisement
Advertisement

ABUS

ABUS logo

Arbutus Biopharma Corporation Common Stock

4.31
USD
Sponsored
0.00
0.00%
May 13, 15:59 UTC -4
Closed
exchange

Pre-Market

4.34

+0.03
+0.70%

Arbutus Biopharma Corporation Common Stock Profile

About

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.

Info & Links

CEO

Lindsay Androski

Headquarters

701 VETERANS CIRCLE
WARMINSTER, PA 18974, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.arbutusbio.com

Auditor

Ernst & Young LLP

Share holders

101

Employees

19

Arbutus Biopharma Corporation Common Stock Statistics

Valuation Measures

Market Capitalization2

854.72M

Enterprise Value

836.71M

Enterprise Value/EBITDA(ttm)

-22.14

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

59.69

Price to Book(mrq)

10.80

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-237.88%

Profit Margin(ttm)

-796.94%

Return on Equity(ttm)

-42.39%

Return on Invested Capital(ttm)

-41.77%

Return on Assets(ttm)

-32.48%

Income Statement

Revenue(ttm)

14.08M

Revenue Per Share(ttm)

0.07

Gross Profit(ttm)

14.08M

EBITDA(ttm)3

-37.80M

Net Income Available to Common(ttm)

-33.50M

Diluted EPS(ttm)

-0.17

Share Statistics

Beta (5Y Monthly)

0.74

52-Week Change

35.11%

S&P 500 52-Week Change

26.33%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

195.48M

Dividend Yield

0.00%

Float4

155.80M

% Held by Insiders

20.30%

% Held by Institutions

43.79%

Balance Sheet

Total Cash(mrq)

91.47M

Total Cash Per Share(mrq)

0.47

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

15.73%

Quick Ratio(mrq)

15.73%

Book Value Per Share(mrq)

0.40

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.21

Free Cash Flow(ytd)

-39.27M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement